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Abstract  
Some data suggest that nocturnal dosing of antihypertensive agents may reduce 
cardiovascular outcomes more than daytime dosing.  This trial was designed to evaluate 
whether ambulatory blood pressure monitoring levels differ by timing of drug dosing. 
Patients aged 18-80 years with reasonably controlled hypertension (<150/<90 mmHg) on 
stable therapy of >1 antihypertensive agent were recruited from two centres in London and 
Thessaloniki.  Patients were randomised to receive usual therapy either in the morning (6am 
– 11am) or evening (6pm – 11pm) for 12 weeks when participants crossed-over to the 
alternative timing for a further 12 weeks. 
Clinic blood pressures and a 24-hour recording were taken at baseline, 12 and 24 weeks and 
routine blood tests were taken at baseline.  The study had 80% power to detect 3mmHg 
difference in mean 24-hour systolic blood pressure (α=0.05) by time of dosing.  A 2-level 
hierarchical regression model adjusted for centre, period and sequence was used. 
Of 103 recruited patients (mean age 52: 44% female), 95 patients (92%) completed all three 
24-hour recordings.  Mean 24-hour systolic and diastolic blood pressures did not differ 
between daytime and evening dosing. Similarly, morning and evening dosing had no 
differential impact on mean daytime (7am – 10pm) and night-time (10pm – 7am) blood 
pressure levels nor on clinic levels. 
Stratification by age (<65/> 65 years) or gender did not affect results. 
In summary, among hypertensive patients with reasonably well-controlled blood pressure, 
the timing of antihypertensive drug administration (morning or evening) did not affect mean 
24-hour or clinic blood pressure levels. 
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Introduction  
Observational data show a strong linear relationship between clinic blood pressure levels and 
subsequent major adverse cardiovascular events⁽¹⁾.  However, ambulatory blood pressure 
monitoring has shown that night-time blood pressure levels are more strongly predictive of 
major adverse cardiovascular events than 24-hour or daytime levels⁽²˒³⁾.  Furthermore, night-
to-day blood pressure ratio and dipping status are also significant independent predictors of 
cardiovascular outcomes⁽⁴⁾.  These findings may have implications for optimal dosing times 
for antihypertensive medications. 
In the MonitorizaciÓn Ambulatoria de la PresiÓn arterial y Eventos Cardiovasculares (MAPEC) 
Study⁽⁵⁾, bedtime dosing of at least one blood pressure-lowering agent compared with only 
morning dosing was associated with better blood pressure control, reduced prevalence of 
non-dipping patterns and reduced morbidity and mortality from cardiovascular events.  The 
results of the placebo-controlled HOPE trial in which the protocol specified that the 
antihypertensive agent (Ramipril) should be given at bedtime, showed that active therapy 
was associated with greater benefits in terms of cardiovascular outcome that would be 
expected from the small reduction in daytime clinic blood pressure observed⁽⁶⁾. 
The Treatment In the Morning versus Evening (TIME) Study⁽⁷⁾ is designed to compare the 
impact on major cardiovascular outcomes of evening dosing of antihypertensive agents than 
morning dosing.  In April 2017 after 25 months of recruitment, the TIME trial completed 
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randomisation of 21,113 patients who are currently being followed up for a mean period of 4 
years.  Meanwhile the Hellenic-Anglo Research into Morning or Night Antihypertensive Drug 
Delivery (HARMONY) trial was designed to evaluate any differential effects of morning versus 
evening dosing on mean 24-hour ambulatory blood pressure levels. 
Methods  
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. [if author providing data is not the corresponding author, please 
provide contact information for that author]. 
This study was a two-centre (London and Thessaloniki), prospective randomised cross-over 
trial of hypertensive men and women who were aged 18-80 years.  Eligibility was dependent 
on patients having hypertension diagnosed at least one year ago and being on stable 
antihypertensive medication (at least one agent with no change for at least three months) 
with reasonably controlled blood pressure levels (systolic < 150 mmHg and > 115 mmHg and 
diastolic < 90 mmHg) and the patients’ physician did not feel further antihypertensive therapy 
was necessary).  Patients with atrial fibrillation and night shift workers were excluded.  Eligible 
patients were randomised to receive their usual medications in the morning (6am to 11am) 
or in the evening (6pm – 11pm) for 12 weeks at which point they crossed over to evening and 
morning dosing respectively, for a further 12 weeks.  Compliance was assessed at 12 and 24 
weeks by self-reporting the number of tablets taken and at what time in the previous 2 weeks.  
Participants were advised to make no changes to their usual diets and lifestyles and other 
drug therapy, which were in place before entry to the trial, unless advised to do so by a 
physician. 
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Written informed consent was obtained from all participants and at baseline three sitting 
blood pressure recordings were taken in the clinic (mean of the last two were used for 
analyses) using standardised methods and machines⁽⁸˒⁹⁾.  In addition, a 24-hour ambulatory 
blood pressure recording was taken prior to baseline using the Spacelabs 90207 and 90217 
machines in London and the TM-2430 (A&D Company Limited) or the BPOne 2.03a (H and C 
Medical Devices Spa) machines in Thessaloniki.  Cuff sizes for ambulatory and clinic blood 
pressure recordings were adjusted according to current UK recommendations (10) and 
manufacturers instructions.  Routine blood samples were taken and an ECG recorded during 
screening to ensure eligibility and at baseline, a quality of life (QoL) questionnaire (EQ-5D-
5L)⁽11⁾ was administered.  At 12 weeks and at the end of the trial any changes in lifestyle, 
medical procedures, visits to a doctor and self-reported serious adverse events were 
recorded.  In addition, at the same time points, the QoL questionnaire was completed and 
clinic blood pressures plus a 24-hour ambulatory blood pressure recording was taken and 
body weight measured. 
The primary end point was change in 24-hour mean systolic blood pressure and secondary 
end points were changes in mean daytime and night-time systolic and diastolic pressures and 
mean sitting clinic systolic and diastolic pressures.  Change in self-reported QoL was also pre-
specified as a secondary endpoint. 
Statistical Methods  
The study was designed to include 100 patients (approximately 50 at each site) in order that 
it would have 80% power (2-sided) at the 5% α level, to detect a 3mmHg difference in mean 
24-hour systolic blood pressure between those taking medication in the morning compared 
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with the evening.  Assumptions included a drop-out rate of 10% and an estimated standard 
deviation (SD) in mean 24-hour systolic blood pressure of 10 mmHg. 
Patient characteristics were summarised as means with SDs for continuous variables and 
frequencies and percentages for categorical variables and data on all patients completing 
both limbs of the trial were included in an intention to treat analyses. 
A 2-level hierarchical regression adjusted for centre, carry over and period effect was used to 
compare the impact of drug dosing time on blood pressure. 
Pre-specified subgroup analyses were carried out by centre (London and Thessaloniki) and 
also post-hoc sensitivity analyses were carried out stratifying by sex, age (<65 years/>65 
years), alternate daytime and night-time windows (9am to 9pm and midnight to 6am), and 
excluding non-white participants and extreme outliers in terms of differences in 24-hour 
systolic blood pressure (those which were greater than 20mmHg when medications were 
taken in the morning compared with the evening). 
Results  
Between July 2013 and January 2015, 103 eligible patients (mean age 62 years, 56% male) 
were randomised (53 in London, 50 in Thessaloniki) in the trial.  At baseline, those randomised 
were taking a mean of 1.9 antihypertensive agents per day (range 1-4).  All patients were 
receiving at least one agent which is recommended for once-daily dosing and 80% were 
receiving at least one agent which provides good 24-hour blood pressure control.  Only eight 
patients were receiving an agent which should ideally be prescribed on a twice daily basis.  
One patient reported any significant lack of compliance prior to their 12-week assessment 
and 3 patients reported incorrect timing of drug dosing on more than 15% of days, one before 
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their 12 week visit and two at their 24 week visit.  Baseline mean clinic blood pressure 
readings of participants showed good control (systolic 128.0 mmHg, SD=8.8; diastolic 76.4 
mmHg, SD=6.1) with a mean body mass index of 29.1Kg/m², SD=5.2, fasting plasma glucose 
of 5.6 mmol/L, SD=0.9 and a non-HDL cholesterol of 3.5 mmol/L, SD=1.0 (Table 1).  There were 
no important or significant differences in baseline variables between the two randomised 
groups (Table 1).  Of those randomised, 95 (92%) completed all three 24-hour ambulatory 
blood pressure recordings. 
Mean 24-hour ambulatory systolic blood pressure did not differ after taking tablets in the 
morning or evening compared with baseline (Table 2).  Similarly, there were no significant 
differences between the two groups in mean 24-hour diastolic blood pressure, mean daytime 
or night-time systolic or diastolic blood pressure, nor in clinic systolic or diastolic blood 
pressure (Table 2). 
There were no changes in QoL score recorded, body weight or heart rates between groups 
and no changes with baseline (data not shown). 
Results were unaffected in sensitivity analyses when data were stratified by centre, age, sex 
and using restricted time windows for day and night-time blood pressures, and excluding one 
South Asian and one black patient or seven extreme outliners (>20 mmHg difference in mean 
24-hour systolic blood pressure recorded after daytime compared with night-time dosing). 
Discussion  
Results of the HARMONY trial suggest that the dosing of routine antihypertensive medication 
in the morning or evening does not affect ambulatory blood pressure levels – whether 24-
hour, daytime or night-time, nor clinic blood pressure levels.  This is, as far as we are aware, 
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the only trial to have evaluated a comparison of the timing of all antihypertensive agents 
currently in use, on 24-hour ABPM levels and conflicts with results of the MAPEC study⁽⁵⁾.  The 
MAPEC study included patients whose blood pressures were uncontrolled whilst receiving 
three antihypertensive agents taken in the morning.  They were randomised to continue to 
receive all three drugs in the morning or to take one of the agents in the evening and two in 
the morning.  After three months, the latter regimen produced significantly lower 24-hour 
mean systolic and diastolic pressures, and reduced major cardiovascular events. 
The large beneficial effects on cardiovascular outcomes observed in the HOPE6 and SYST-
EUR12 trials have been considered by some to be attributable to the nocturnal dosing used 
preferentially in these trials but no randomised evaluation of day versus night dosing was 
incorporated into these trials.  In a trial of 41 patients with obstructive sleep apnoea and 
newly diagnosed hypertension, patients received one or two agents as a morning dose for 
eight weeks, followed by the same treatment as an evening dose, for a further eight weeks13.  
The second eight-week period was associated with significantly lower clinic and 24-hour blood 
pressures but the non-randomised design precludes the definitive conclusion that the 
benefits accrued from the dosing time, rather than an order effect. 
There were only two non-Caucasian patients (one black and one South Asian) among the 
HARMONY participants and particularly in view of the known lower rates of nocturnal dipping 
among black patients⁽¹4⁾, the results of this trial may not be generalisable to ethnic groups 
other than Caucasian.   
This trial was relatively small, with 80% power to detect a 3mmHg difference in 24-hour 
systolic blood pressure between morning and evening dosing.  Furthermore, it is possible that 
if the 1.62 mmHg lower night-time systolic blood pressure associated with evening dosing 
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(Table 2) reflects a real difference, this could translate into lower rates of cardiovascular 
outcomes, as suggested by epidemiological observations⁽2˒3⁾.  However, all analyses with or 
without adjustment and among subgroups were consistent in suggesting limited, if any, 
differences in blood pressures related to dosing time. 
This apparently neutral effect could reflect the small average number of agents being used 
(<2) by the HARMONY patients and their good blood pressure control at baseline.  
Furthermore, since participants were recruited from two specialist hypertension centres, the 
drugs routinely prescribed were, in keeping with currently recommended best practice⁽⁸˒⁹˒¹5⁾, 
very largely long-acting agents providing good 24-hour control.  This in turn might minimise 
any 24-hour blood pressure difference based on dosing times.  By contrast, in settings in 
which agents with shorter durations of action are more commonly used, dosing times may 
more likely affect 24-hour blood pressure control (assuming differential effects of such agents 
when given at day or night time). 
It remains to be seen whether these possible limitations of the HARMONY trial will be 
reflected in the results of the TIME trial (7) in which large numbers of patients recruited from 
more population-based settings throughout the UK have been randomised. 
Meanwhile, it seems reasonable to conclude that the timing of dosing of antihypertensive 
medications should be primarily based on whichever time suits the patient best whilst using 
as simple a regimen as possible, and long acting agents. 
Perspectives   
The results of the HARMONY trial suggest that the impact of antihypertensive medications on 
24-hour ambulatory blood pressure levels is unaffected by whether medications are taken in 
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the morning or evening.  In light of the trial inclusion criteria and demography of participants 
these findings maybe only applicable to white Caucasian patients with reasonably well 
controlled blood pressure levels. 
These results may be in-part dependant on the predominant use of long-acting formulations 
of agents.  Nevertheless, these findings appear reasonably robust given the trial had 80% 
power to detect a 3mmHg difference in 24-hour systolic blood pressure between randomised 
groups, high rates of adherence (albeit self-reported) and 92% of participants completing all 
three 24-hour blood pressure recordings.  Furthermore, the lack of impact of morning versus 
evening dosing was consistent across all types of blood pressure measurements and in all 
sensitivity analyses.   
By contrast, extensive epidemiological data suggest that night-time blood pressure levels 
predict cardiovascular outcomes better than daytime or 24-hour levels and therefore a link 
between night-time drug dosing levels and preferential cardiovascular outcomes has been 
made.  The results of the large TIME trial which is evaluating the impact of daytime versus 
night-time dosing on major cardiovascular events are required to see definitively whether 
night-time dosing does impart important benefits.  Meanwhile there is no reason to expect 
specific drug timing to improve blood pressure control, except presumably if the timing 
adversely affects drug compliance at the individual level.   
Therefore, pending further evidence patients should be advised to take their antihypertensive 
medications when it best suits them. 
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Novelty and significance  
1. What is new?  This is the first randomised trial to evaluate and to show that taking 
usual blood pressure-lowering medications either all in the evening or in the morning 
did not impact on 24-hour ambulatory blood pressure levels or clinic blood pressure 
levels. 
2. What is relevant?  Epidemiological data suggest that nocturnal blood pressure levels 
predict adverse cardiovascular outcomes better than daytime levels and hence the 
possible preferential use of night-time drug dosing has been suggested. 
3. Summary.  Pending further definitive evidence (particularly the results of the TIME 
trial) patients should take their antihypertensive medications at a time which 
optimises adherence. 
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Table 1 Baseline characteristics by order of dosing schedule 
 
Variable* Evening / Morning Morning / Evening Total 
Number (N) 52 51 103 
Age 62.8 (9.7) 61.8 (11.0) 61.8 (10.3) 
Female, N (%) 21 (40) 24 (47) 45 (44) 
BMI 29.1 (5.6) 29.1 (4.7) 29.1 (5.2) 
Heart rate 72.8 (10.3) 72.7 (9.6) 72.7 (9.9) 
Systolic BP 127.1 (8.7) 129.0 (8.8) 128.0 (8.8) 
Diastolic BP 76.6 (6.1) 76.3 (6.2) 76.4 (6.1) 
Current smoker, N (%) 4 (8) 8 (8) 12 (12) 
Alcohol units per week 16.7 (17.2) 11.8 (11.9) 14.6 (15.2) 
Fasting plasma glucose 5.6 (0.9) 5.5 (1.0) 5.6 (0.9) 
Non-HDL cholesterol 3.4 (1.0) 3.5 (1.0) 3.5 (1.0) 
 
*Mean (Standard Denation) except where specified 
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Table 2 Blood pressure levels (mmHg) by timing of dosing schedules 
 
Outcome mmHg 
(N=95) 
Baseline Drug taken Observed difference 
(Evening - Morning) 
*Adjusted difference 
(95%CI) 
Morning Evening 
24h Systolic BP 128.64 129.65 129.75 0.10 0.11 (-3.20, 3.42) 
24h Diastolic BP 76.92 77.24 77.99 0.75 0.77 (-1.38, 2.91) 
Daytime SBP 131.16 132.24 132.77 0.53 0.54 (-2.82, 3.89) 
Daytime DBP 79.14 79.27 80.55 1.28 1.30 (-0.96, 3.56) 
Night-time SBP 120.89 122.76 121.08 -1.68 -1.62 (-5.38, 2.15) 
Night-time DBP 69.83 70.92 70.57 -0.35 -0.32 (2.81, 2.17) 
Clinic SBP 128.07 129.37 129.81 0.44 0.39 (-2.91, 3.69) 
Clinic DBP 76.54 77.26 77.41 0.15 0.14 (-2.03, 2.32) 
QoL Score 82.8 84.14 84.04 -0.10 -0.12 (-3.12, 2.89) 
 
 
*Site, period (visit) and sequence (group)  
 
